The POC Diagnostics Market is expected to grow from an estimated USD 51.26 billion in 2024 to USD 118.91 billion in 2033, at a CAGR of 9.8%. The global point-of-care (POC) diagnostics market is ...

The global HIV diagnostics market, valued at US$2.96B in 2024, is forecasted to grow at a 10.3% CAGR, reaching US$3.25B by ...

Diagnostics giant Roche led the round for South San Francisco ... used to fund the development of its lead drug bezuclastinib, a KIT inhibitor heading for a phase 2 readout later this year in ...

Roche Diagnostics is collaborating with the University of Liverpool to launch the Eye Cancer Artificial Intelligence Digital ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...

The Diagnostic Specialty Enzymes Market was valued at US$ 1.0 billion in 2022 and is projected to grow at a CAGR of 6.9% from ...

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.

CVRM product development global head and senior vice-president Manu Chakravarthy will be the centre's site head.

Newsweek is partnering with Plant-A Insights Group to recognize America's Most Loved Brands 2025. These brands not only ...

The "Cell Counting Market by Product (Instruments (Spectrophotometer, Flow Cytometer, Hematology Analyzers, Cell Counters), ...

They’re going to try The devices are manufactured by the Marina del Rey-based medical diagnostics company Defense Diagnostics Inc. The portable, single-use Defent One device is small enough to ...